As Southern California’s life-sciences ecosystem grows, Orange County has become a source of development — but is falling ...

Shares of Edwards Lifesciences Corp. EW rose 6.63% to $75.13 Thursday, on what proved to be an all-around great trading ...

Q1 2025 Management View CEO Bernard Zovighian outlined that total company sales grew 8% to $1.41 billion in Q1 2025, driven ...

Fintel reports that on April 24, 2025, Piper Sandler upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Neutral ...

Edwards Lifesciences raised 2025 revenue forecast after Q1 results beat EPS estimates and TMTT sales jumped 58% amid strong ...

Analysts are estimating that Edwards Lifesciences will report an earnings per share (EPS) of $0.59. The announcement from ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Edwards Lifesciences (EW – Research Report), Resmed (RMD – ...

Canaccord analyst William Plovanic raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $71. The firm said Edwards delivered ...

Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment.

The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

Edwards Lifesciences (NYSE: EW) shares stayed put after hours today on first-quarter results that beat Wall Street ...

Edwards Lifesciences Price Performance Shares of EW opened at $71.56 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a ...